Scott Smith
@Acuta Capital Partners, Llc
Latest period2024 - Q3ReportedManaged Assets$123.464MTotal holdings41
Assets growth rate3.99%Assets growth rate (2-Q avg)-9.44%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Acuta Capital Partners, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.
Assets under management
The assets under management (AUM) of Acuta Capital Partners, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 123.464M in assets, with a quarterly growth rate of 3.99% and a 2-quarter average growth rate of -9.44%. The portfolio is managed by Scott Smith, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
OCULOcular Therapeutix Inc
| 8.39% | $10.354M 1.19M shares@ $8.71 avg price | Decreased -57.05% |
ELVNEnliven Therapeutics Inc
| 6.14% | $7.569M 296,368 shares@ $25.55 avg price | Decreased -25.47% |
CRNXCrinetics Pharmaceuticals In
| 5.46% | $6.73M 131,700 shares@ $51.1 avg price | Decreased -2.54% |
RVMDRevolution Medicines Inc
| 3.97% | $4.898M 108,000 shares@ $45.35 avg price | Decreased -18.79% |
TSHATaysha Gene Therapies Inc
| 3.45% | $4.259M 2.119M shares@ $2.02 avg price | Decreased -9.09% |
RCKTRocket Pharmaceuticals Inc
| 2.85% | $3.509M 190,000 shares@ $18.47 avg price | Decreased -24.11% |
PRAXPraxis Precision Medicines I
| 2.68% | $3.309M 57,500 shares@ $57.54 avg price | Decreased -65.03% |
MRSNMersana Therapeutics Inc
| 1.84% | $2.268M 1.2M shares@ $1.89 avg price | Decreased -27.84% |
DYNDyne Therapeutics Inc
| 1.35% | $1.66M 46,200 shares@ $35.92 avg price | Decreased -78.25% |
CRBPCorbus Pharmaceuticals Holdings
| 0.31% | $381,655 18,500 shares@ $20.63 avg price | Decreased -71.31% |